Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) as adjunctive therapy to insulin significantly reduce body weight, HbA1c, and total daily insulin requirements in patients with type 1 diabetes and overweight or obesity.

If you have Type 1 Diabetes and are overweight, adding a GLP-1RA (like semaglutide or liraglutide) to your insulin regimen can help you lose weight (average 4-6 kg), lower your HbA1c slightly, and significantly reduce your daily insulin needs (by ~9 units). This is generally safe, though you may experience temporary nausea and a slightly higher risk of low blood sugar, which can be managed by adjusting your insulin dose.

Semaglutide demonstrates superior efficacy in reducing body weight, HbA1c, and insulin requirements compared to other GLP-1RAs (liraglutide, exenatide) in patients with Type 1 Diabetes.

Among GLP-1RAs, semaglutide (1.0 mg weekly) appears to be the most effective option for Type 1 Diabetes patients, offering greater weight loss (~6 kg) and insulin reduction (~15 units/day) compared to liraglutide or exenatide. Discuss with your provider if you are a candidate for this specific agent.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces dose-dependent reductions in body weight (up to 9.8% at 45 mg) and waist circumference, with maximal efficacy observed at higher doses (24-45 mg).

Orforglipron is an oral medication that helps obese adults lose weight and improve metabolic markers like blood sugar and cholesterol. It works by mimicking a natural hormone (GLP-1) to reduce appetite and slow digestion. The higher the dose (up to 45 mg daily), the more weight is lost, with studies showing up to 9.8% body weight reduction. However, higher doses also increase the risk of stomach issues like nausea and diarrhea, which may lead some patients to stop taking it. It is taken once daily without strict fasting requirements, making it more convenient than some injectable alternatives.

Treatment with semaglutide 2.4 mg for overweight or obesity leads to a statistically significant reduction in the need for concomitant antihypertensive and lipid-lowering medications compared to placebo, primarily through weight-loss-mediated improvements in blood pressure and lipid profiles.

If you are taking medication for high blood pressure or high cholesterol, significant weight loss achieved through semaglutide 2.4 mg may allow your doctor to safely lower your dose or stop the medication entirely. This is not automatic; it requires active monitoring by your healthcare provider to ensure your blood pressure and lipids remain in a healthy range without the drugs. Do not stop these medications on your own.

Intentional weight loss achieved through lifestyle interventions, antiobesity medications, or bariatric surgery reduces the incidence of obesity-associated cancers, particularly hormone-dependent malignancies in postmenopausal women.

If you have overweight or obesity, achieving and maintaining a weight loss of at least 5% of your body weight can significantly reduce your risk of developing certain cancers, especially in postmenopausal women. This can be achieved through lifestyle changes (diet and exercise), medications, or surgery. The key is sustained loss, not just short-term dieting.

Higher protein diets during weight loss improve glycemic variables (fasting triglycerides and insulin) compared to standard protein diets, with benefits persisting to some degree long-term.

When losing weight, choosing a diet with higher protein content can help improve your metabolic health, specifically by lowering fasting triglycerides and insulin levels. This benefit may persist even after the diet ends. Focus on increasing protein intake as part of a balanced approach to weight loss.

Phenotype-guided pharmacotherapy using naltrexone/bupropion extended-release (NB-ER) is the preferred treatment for obesity patients with emotional hunger, as it addresses both weight and depression symptoms.

If you struggle with emotional eating and depression, ask your doctor about NB-ER (naltrexone/bupropion). It is specifically shown to help with both weight loss and mood in this subgroup, unlike many standard antidepressants which may cause weight gain.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) are effective for weight loss in patients with obesity and may improve depression scores, with a low rate of adverse psychiatric events.

GLP-1 agonists (like Semaglutide or Tirzepatide) are highly effective for weight loss (15-21%) and may also improve depression. They have a low risk of psychiatric side effects. Discuss these with your doctor if you have no thyroid cancer history.

Semaglutide (2.4 mg once-weekly) produces significant, sustained weight loss (10-15%) and improves cardiometabolic markers in non-diabetic individuals with obesity or overweight, primarily by mimicking GLP-1 to reduce appetite and energy intake.

If you have obesity or are overweight without diabetes, semaglutide (2.4 mg weekly) is a highly effective medical treatment that can help you lose 10-15% of your body weight and improve your metabolic health. It works by reducing your appetite. While it can cause temporary stomach issues like nausea, these often subside. It works best when combined with diet and exercise, but it is significantly more effective than lifestyle changes alone for substantial weight loss.

GLP-1 receptor agonists (semaglutide) and dual incretin agonists (tirzepatide) achieve 15-20% total body weight loss, rivaling the efficacy of bariatric surgery.

If you have obesity, these medications offer a powerful, non-surgical path to significant weight loss (15-20%). They require a weekly injection and likely lifelong use, but they can improve metabolic health and may be more accessible than surgery for some. Discuss with your doctor if you are a candidate.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce significantly greater average weight loss (14.9% and 18.5%, respectively) than physicians estimate (9.22%), and are associated with high rates of gastrointestinal side effects (80-90%) that are significantly underestimated by prescribers.

If you are prescribing GLP-1 agonists, ensure you are counseling patients on the high likelihood of gastrointestinal side effects (up to 90%) and the significant magnitude of weight loss (15-18%). Underestimating these factors leads to poor adherence and unrealistic expectations.

Incretin medications (GLP-1 RAs and dual agonists) are the most effective class of AOMs for older adults, achieving 15-25% weight loss, but require careful titration to manage side effects.

Incretin drugs like Semaglutide and Tirzepatide are currently the most effective weight loss medications for older adults, often resulting in 15-25% body weight loss. They work by mimicking gut hormones to reduce hunger. Doctors usually start with a low dose to minimize side effects like nausea and gradually increase it.

Phentermine/topiramate and naltrexone/bupropion are effective alternative pharmacotherapies for weight loss (4-10%) in patients without cardiovascular contraindications, offering oral administration options.

If you cannot take or afford weekly injections, oral medications like phentermine/topiramate or naltrexone/bupropion are effective alternatives. They typically result in 4-10% weight loss. Side effects like nausea or insomnia are common but often improve over time, especially if you start with a low dose and increase slowly. These are not suitable if you have heart disease, high blood pressure, or a history of seizures.

Supplementation with 5g/day spinach-derived thylakoid membranes combined with a hypo-caloric diet significantly improves atherogenic indices (AIP, CRI-I, CRI-II) and insulin resistance surrogates (TyG-BMI, METS-IR) in obese women with PCOS compared to placebo.

If you have PCOS and are overweight, adding 5 grams of spinach thylakoid extract daily to your calorie-restricted diet may help improve your blood vessel health markers and insulin sensitivity more than dieting alone. Take it 30 minutes before lunch.

Tirzepatide (5, 10, or 15 mg once weekly) provides significantly longer continuous time in glycaemic control (HbA1c <7.0% and ≤6.5%) and sustained body weight reduction (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies in patients with type 2 diabetes.

For patients with Type 2 Diabetes, tirzepatide (5, 10, or 15 mg once weekly) offers significantly longer periods of stable blood sugar (HbA1c <7.0%) and sustained weight loss (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies. This suggests that tirzepatide may provide more durable disease management with fewer hypoglycaemic events than insulin.

Resistance exercise followed immediately by protein feeding significantly increases phosphorylation of Akt Ser473, p70S6K1 Thr412, and rpS6 Ser235/236 in human skeletal muscle, with the combined stimulus producing greater or more sustained signaling than feeding alone.

To maximize the cellular signaling for muscle growth, combine resistance exercise with protein intake. This study shows that doing both together triggers a stronger and more sustained activation of key muscle-building pathways (mTORC1) than eating protein alone. Specifically, performing resistance training followed by a protein-containing meal leads to higher levels of signaling molecules like Akt and p70S6K1, which are critical for muscle protein synthesis.

Semaglutide (Ozempic/Wegovy) promotes significant weight loss (10-15% body weight) and improves glycemic control in adults with type 2 diabetes or obesity through GLP-1 receptor agonism, delayed gastric emptying, and appetite suppression.

Semaglutide is a once-weekly injection that mimics a gut hormone to slow digestion and reduce appetite. It is clinically proven to help people with obesity or type 2 diabetes lose 10-15% of their body weight when combined with diet and exercise. Side effects like nausea are common initially but often subside; starting with a low dose helps manage this. It is not a substitute for lifestyle changes but a tool to facilitate them.

Tirzepatide produces significantly greater weight loss than semaglutide and liraglutide in patients with obesity or type 2 diabetes.

If you are struggling with obesity or type 2 diabetes, tirzepatide (administered weekly at doses up to 15 mg) has demonstrated superior weight loss capabilities compared to semaglutide and liraglutide in clinical trials. To maximize results, combine this pharmacotherapy with lifestyle changes, including a caloric deficit, regular physical activity, and behavioral modifications.

GLP-1 receptor agonists (GLP-1RA) and related incretin mimetics (e.g., semaglutide, tirzepatide, retatrutide) produce significant weight loss in adults with obesity, achieving reductions comparable to bariatric surgery.

GLP-1 medications like Semaglutide and Tirzepatide are highly effective for weight loss, often achieving 15-24% body weight reduction, which rivals bariatric surgery. They work by increasing satiety and slowing digestion. Because obesity is chronic, these drugs likely need to be taken long-term to maintain weight loss. Side effects are mostly gastrointestinal (nausea), but serious risks exist for those with specific thyroid cancer histories. Consult a doctor to see if you are a candidate.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) produce substantial weight loss and metabolic improvements in patients with severe mental illness experiencing antipsychotic-induced weight gain, without exacerbating psychiatric symptoms.

For patients with severe mental illness struggling with antipsychotic-induced weight gain, GLP-1 receptor agonists like semaglutide offer a highly effective treatment option that reduces weight significantly without worsening mental health symptoms. While side effects like nausea are common, they are often mild and transient. The main barrier is often cost and insurance coverage, so patients and providers should advocate for access to these medications as a standard part of care for this population.

Sibutramine, an appetite suppressant acting on the hypothalamus, is more effective than placebo for weight loss when combined with lifestyle changes, with 22-38% of patients achieving >5% weight loss in 3 months.

Sibutramine helps you lose weight by reducing appetite. About 22-38% of users lose more than 5% of their body weight in 3 months. It is not safe for people with heart problems or high cardiovascular risk. Side effects include increased blood pressure and dry mouth.

Bupropion/Naltrexone combination therapy results in a mean weight loss of 6.1% over 56 weeks in obese or overweight adults, significantly better than placebo (1.3%).

Bupropion/Naltrexone helps you lose about 6% of your body weight over a year. It works by reducing appetite and food cravings. It is not safe for people with seizure disorders, uncontrolled high blood pressure, or those taking certain antidepressants. Side effects like nausea are common but often temporary.

Semaglutide (subcutaneous 1 mg/week and oral 14 mg/day) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with subcutaneous administration showing superior efficacy compared to other GLP-1 receptor agonists.

Semaglutide is a highly effective GLP-1 receptor agonist for lowering blood sugar (HbA1c) and reducing body weight in type 2 diabetes patients. It is available in both weekly injections (1 mg) and daily oral tablets (14 mg), with the injection showing slightly greater efficacy. For obese non-diabetics, a higher injection dose (2.4 mg) leads to significant weight loss (~15%). While nausea is a common side effect, it is usually manageable. Patients with pre-existing eye disease (retinopathy) should use it cautiously due to a potential increased risk of retinal complications.

GLP-1 agonists (semaglutide, liraglutide, tirzepatide) produce significantly greater weight loss than placebo when combined with lifestyle modifications in adults and adolescents without type 2 diabetes.

If you have obesity and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or tirzepatide are significantly more effective than placebo when combined with diet and exercise. Expect side effects like nausea, which are usually manageable, and commit to a treatment duration of at least 5-7 months to see full results.